HALO:BMV
Halozyme Therapeutics, Inc.
MX$1,955.00
arrow_downward
-0.70%(-13.69) 1D
Oct 1, 1:46:16 PM GMT-6 · MXN
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HALO...
Mkt. cap
12.53B
Avg. vol.
440.00
Volume
0.00
52-wk high
MX$1,970.00
52-wk low
MX$1,121.86
No. of employees
423
Mkt. cap
12.53B
Avg. vol.
440.00
Volume
0.00
52-wk high
MX$1,970.00
52-wk low
MX$1,121.86
No. of employees
423
News stories
From web sources and news partners
ChartMill
·
12 hours ago
Halozyme Therapeutics (NASDAQ:HALO): A Decent Value Stock With Strong Profitability
Investing.com Nigeria
·
20 hours ago
Form 4 Halozyme Therapeutics Inc For: 8 October By Investing.com
Investing.com
·
21 hours ago
Halozyme CEO Helen Torley sells $6.61m in shares
Stock Titan
·
23 hours ago
A director received 3,796 stock units at Halozyme (HALO), not the 6,796 originally reported.
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websitehalozyme.com